<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593279</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL14_0212</org_study_id>
    <nct_id>NCT02593279</nct_id>
  </id_info>
  <brief_title>AVAD: Asthma With Small Airways Dysfunction</brief_title>
  <acronym>AVAD</acronym>
  <official_title>AVAD: Asthma With Small Airways Dysfunction. Clinical, Immunobiological, Tomodensitometric Description, Genetic Signature Compared With Asthmatic Population With Proximal Airways Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to describe asthma phenotype with small airways dysfunction, in a
      multiparametric manner, with clinical, biological, morphological and genetic elements
      compared with asthma with proximal airways obstruction.

      The objective of this study is also to complete the clinical, immunobiological and
      morphological analysis of asthma with small airways dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mRNA expression levels.</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>mRNA expression levels will be measured by microarray analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical asthma profile : symptoms</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical asthma profile : medical history</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>medical history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical asthma profile : date of start</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>date of start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical asthma profile : date of aggravation</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>date of aggravation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical asthma profile : comorbidities</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>comorbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical asthma profile : increased factors related to asthma.</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>increased factors related to asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological asthma profile :blood eosinophils</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>blood eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological asthma profile : blood periostin</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>blood periostin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological asthma profile : allergologic patch test</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>allergologic patch test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological asthma profile : IgE analysis</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>IgE analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morphological asthma profile : Chest X Ray (tomodensitometric test).</measure>
    <time_frame>maximum 4 weeks after the inclusion visit.</time_frame>
    <description>Chest X Ray (tomodensitometric test).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ASTHMA</condition>
  <arm_group>
    <arm_group_label>asthma with proximal or diffuse lung damage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>asthma with small airway prevailing damage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.</intervention_name>
    <description>symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.</description>
    <arm_group_label>asthma with proximal or diffuse lung damage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.</intervention_name>
    <description>symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.</description>
    <arm_group_label>asthma with small airway prevailing damage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  man or woman

          -  age ≥ 18 years

          -  asthma

          -  inform consent signed

          -  affiliated to health insurance

        Specific inclusion criteria : asthma with proximal airways obstruction GROUP

          -  Maximal Voluntary Ventilation (MMV)&lt;80%

          -  MMV / Forced Vital Capacity (FVC)≤70%

          -  Carbon Monoxide Transfer Coefficient (KcO)&gt;80%

        Specific inclusion criteria : asthma with small airways dysfunction GROUP

          -  Maximal Voluntary Ventilation (MMV)≥80%

          -  MMV / Vital Capacity(VC)&gt;70%

          -  Carbon Monoxide Transfer Coefficient (KcO)&gt;80%

        General Exclusion Criteria:

          -  pregnant woman or breastfeeding

          -  patient participating to other biomedical research

          -  patient who have participated to other biomedical research within the past 3 months

          -  patient refusing to sign the inform consent

        Specific exclusion criteria :

          -  Patient who stopped smoking since less than 12 months

          -  Pathological state related to obstructive distal airway damage

          -  Broncho-pulmonary infectious disease within the past 4 weeks

          -  Solid tumor curated by chemotherapy or chest radiotherapy

          -  Chronic respiratory disease

          -  Asthma exacerbation within the past 3 months

          -  Oral or systemic corticotherapy within the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GILLES DEVOUASSOUX, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GILLES DEVOUASSOUX, Pr</last_name>
    <phone>426732947</phone>
    <email>gilles.devouassoux@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ISABELLE DELFOUR</last_name>
    <phone>426732725</phone>
    <phone_ext>+33</phone_ext>
    <email>isabelle.delfour@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cabinets de Pneumologie Liberale</name>
      <address>
        <city>Caluire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gérard CHATTE, MD</last_name>
      <phone>472362093</phone>
      <phone_ext>+33</phone_ext>
      <email>gerard.chatte@pneumologuesacaluire.fr</email>
    </contact>
    <investigator>
      <last_name>Gérard CHATTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles DEVOUASSOUX, Pr</last_name>
      <phone>426732947</phone>
      <phone_ext>+33</phone_ext>
      <email>gilles.devouassoux@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle DELFOUR</last_name>
      <phone>426732725</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.delfour@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles DEVOUASSOUX, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CABINETS DE PNEUMOLOGIE LIBERALE HIA Desgenettes</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Marc DOT, MD</last_name>
      <phone>472362093</phone>
      <phone_ext>+33</phone_ext>
      <email>jmdot@free.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Marc DOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HC pneumo C</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Nathalie, MD</last_name>
      <phone>478861609</phone>
      <phone_ext>+33</phone_ext>
      <email>nathalie.freymond@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Nathalie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves PACHECO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2015</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>phenotype</keyword>
  <keyword>small</keyword>
  <keyword>airway</keyword>
  <keyword>proximal</keyword>
  <keyword>dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

